Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $10.75.

ZURA has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. Wall Street Zen downgraded shares of Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Chardan Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research report on Friday, November 14th. Finally, Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd.

Zura Bio Trading Down 7.0%

Shares of ZURA stock opened at $5.98 on Thursday. The stock has a market cap of $388.82 million, a P/E ratio of -9.20 and a beta of 0.20. Zura Bio has a 1 year low of $0.97 and a 1 year high of $6.63. The stock has a 50 day simple moving average of $4.64 and a 200 day simple moving average of $3.34.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Analysts forecast that Zura Bio will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Zura Bio

Several large investors have recently modified their holdings of the business. Scientech Research LLC bought a new position in Zura Bio during the 3rd quarter worth $45,000. Forefront Wealth Partners LLC acquired a new stake in shares of Zura Bio in the third quarter valued at about $93,000. Squarepoint Ops LLC acquired a new stake in shares of Zura Bio in the third quarter valued at about $109,000. Qube Research & Technologies Ltd bought a new position in shares of Zura Bio during the third quarter worth about $138,000. Finally, Savant Capital LLC lifted its stake in shares of Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after acquiring an additional 21,249 shares during the period. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.